Literature DB >> 9817703

8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases.

P Montuschi1, G Ciabattoni, P Paredi, P Pantelidis, R M du Bois, S A Kharitonov, P J Barnes.   

Abstract

Oxidative stress contributes to the pathophysiology of interstitial lung diseases, such as cryptogenic fibrosing alveolitis (CFA), fibrosing alveolitis associated with systemic sclerosis (FASSc) and sarcoidosis. F2-isoprostanes are a series of prostaglandin (PG) F2-like compounds produced in vivo independent of cyclooxygenase, as products of the radical-catalyzed lipid peroxidation. Measurement of the concentrations of F2-isoprostanes has proved to be valuable in assessing oxidative stress in vivo. The aim of this study was to measure 8-epi-PGF2alpha concentrations, one of the most abundant F2-isoprostane in humans, in bronchoalveolar lavage (BAL) in normal subjects and to compare them to those observed in patients with CFA (n = 9), FASSc (n = 8) and sarcoidosis (n = 10). 8-epi-PGF2alpha was detectable in BAL fluid in normal subjects (9.6 +/- 0.8 pg/ml) and its concentrations were increased approximately 5-fold in patients with CFA (47.4 +/- 7.0, p < 0.001) and FASSc (43.2 +/- 3.3, p < 0. 001). 8-epi-PGF2alpha was also increased in patients with sarcoidosis, although to a lesser extent (12.0 +/- 0.70 pg/ml, p < 0. 01). No correlation between 8-epi-PGF2alpha and either lung function tests or BAL cell types was observed in any group of patients. Our study shows that the level of oxidative stress is enhanced in patients with interstitial lung diseases as reflected by increased concentrations of 8-epi-PGF2alpha in BAL fluid.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817703     DOI: 10.1164/ajrccm.158.5.9803102

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  53 in total

1.  Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma.

Authors:  L G Wood; D A Fitzgerald; P G Gibson; D M Cooper; M L Garg
Journal:  Lipids       Date:  2000-09       Impact factor: 1.880

2.  Effects of combined hyperoxia and cyclooxygenase inhibition in neonatal rat lungs.

Authors:  Katherine M Kuniyoshi; Romy S Brock; Bisrat H Gebrekristos; Matthew Abad-Santos; Dinh Hoang; Houchang D Modanlou; Brigham C Willis; Kay D Beharry
Journal:  Am J Transl Res       Date:  2010-06-08       Impact factor: 4.060

3.  Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias.

Authors:  N Yoshimi; Y Ikura; Y Sugama; S Kayo; M Ohsawa; S Yamamoto; Y Inoue; K Hirata; H Itabe; J Yoshikawa; M Ueda
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

4.  Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness.

Authors:  Mónica de la Peña Bravo; Laura D Serpero; Antonia Barceló; Ferran Barbé; Alvar Agustí; David Gozal
Journal:  Sleep Breath       Date:  2007-09       Impact factor: 2.816

5.  Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles.

Authors:  L J Janssen; M Premji; S Netherton; J Coruzzi; H Lu-Chao; P G Cox
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

6.  Apigenin attenuates streptozotocin-induced pancreatic β cell damage by its protective effects on cellular antioxidant defense.

Authors:  Ning Wang; Wen Jing Yi; Lu Tan; Jia Hui Zhang; Jiamin Xu; Yi Chen; Mengting Qin; Shuang Yu; Jing Guan; Rui Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-02-08       Impact factor: 2.416

Review 7.  Extracellular superoxide dismutase in pulmonary fibrosis.

Authors:  Fei Gao; Vuokko L Kinnula; Marjukka Myllärniemi; Tim D Oury
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

8.  Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up.

Authors:  Wojciech J Piotrowski; Zofia Kurmanowska; Adam Antczak; Jerzy Marczak; Paweł Górski
Journal:  BMC Pulm Med       Date:  2010-04-27       Impact factor: 3.317

Review 9.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.